Literature DB >> 33141955

Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.

Tingting Lv1, Sha Chen1, Min Li2, Dong Zhang3, Yuanyuan Kong2, Jidong Jia1.   

Abstract

BACKGROUND AND AIM: We aimed to estimate the worldwide incidence and prevalence, with focus on the geographical differences and temporal trends.
METHODS: Studies on epidemiology of primary biliary cholangitis (PBC) in PubMed, Embase, and Cochrane Library were systematically retrieved from inception to October 2, 2020. Random-effect model was applied to estimate the pooled PBC incidence and prevalence rates. Subgroup analysis, meta-regression, and sensitivity analysis were conducted to find out the cause for heterogeneity.
RESULTS: Out of 3974 records identified through database searching, 47 population-based studies were finally included. The pooled global incidence and prevalence of PBC were 1.76 and 14.60 per 100 000 persons, respectively. Both the PBC incidence and prevalence were lower in the Asia-Pacific region (0.84, 9.82 per 100 000 persons) than that in North America (2.75, 21.81 per 100 000 persons) and Europe (1.86, 14.59 per 100 000 persons) (P < 0.05). The incidence and prevalence showed an increasing tendency in all three regions, with the fastest growth of prevalence in North America (P < 0.05). We found a similar incidence and a lower prevalence of PBC in Northern Europe than that in Southern Europe. A higher incidence and prevalence were observed in female individuals and in the elderly (60-79).
CONCLUSION: The PBC incidence and prevalence varied widely across regions, with North America being the highest, followed by Europe, and the lowest in the Asia-Pacific region. Both the incidence and prevalence showed an increasing tendency worldwide, especially in North America.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  epidemiology; incidence; meta-analysis; prevalence; primary biliary cholangitis

Year:  2020        PMID: 33141955     DOI: 10.1111/jgh.15329

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.

Authors:  Zi-Long Wang; Kai-Min Song; Rui Jin; Yan-Di Xie; Yu-Qiong Wang; Zhi-Cheng Liu; Bo Feng
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

Review 2.  Roles of Non-Coding RNAs in Primary Biliary Cholangitis.

Authors:  Yaqin Zhang; Ziying Jiao; Mingwei Chen; Bing Shen; Zongwen Shuai
Journal:  Front Mol Biosci       Date:  2022-07-08

3.  Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China.

Authors:  Zi-Xuan Shen; Dan-Dan Wu; Jie Xia; Xian-Bo Wang; Xin Zheng; Yan Huang; Bei-Ling Li; Zhong-Ji Meng; Yan-Hang Gao; Zhi-Ping Qian; Feng Liu; Xiao-Bo Lu; Jia Shang; Hua-Dong Yan; Yu-Bao Zheng; Wen-Yi Gu; Yan Zhang; Jian-Yi Wei; Wen-Ting Tan; Yi-Xin Hou; Qun Zhang; Yan Xiong; Cong-Cong Zou; Jun Chen; Ze-Bing Huang; Xiu-Hua Jiang; Sen Luo; Yuan-Yuan Chen; Na Gao; Chun-Yan Liu; Wei Yuan; Xue Mei; Jing Li; Tao Li; Xin-Yi Zhou; Guo-Hong Deng; Jin-Jun Chen; Xiong Ma; Hai Li
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

Review 4.  Update on the Pharmacological Treatment of Primary Biliary Cholangitis.

Authors:  Annarosa Floreani; Daniela Gabbia; Sara De Martin
Journal:  Biomedicines       Date:  2022-08-20

Review 5.  The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis.

Authors:  Jakub Gazda; Sylvia Drazilova; Martin Janicko; Peter Jarcuska
Journal:  Can J Gastroenterol Hepatol       Date:  2021-06-19

6.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.